Blaszkowsky LS - Search Results

1

Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers.

Parikh AR, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, Livitz D, Rhrissorrakrai K, Martin EE, Van Seventer EE, Hanna M, Slowik K, Utro F, Pinto CJ, Wong A, Danysh BP, de la Cruz FF, Fetter IJ, Nadres B, Shahzade HA, Allen JN, Blaszkowsky LS, Clark JW, Giantonio B, Murphy JE, Nipp RD, Roeland E, Ryan DP, Weekes CD, Kwak EL, Faris JE, Wo JY, Aguet F, Dey-Guha I, Hazar-Rethinam M, Dias-Santagata D, Ting DT, Zhu AX, Hong TS, Golub TR, Iafrate AJ, Adalsteinsson VA, Bardelli A, Parida L, Juric D, Getz G, Corcoran RB. Parikh AR, et al. Among authors: blaszkowsky ls. Nat Med. 2019 Sep;25(9):1415-1421. doi: 10.1038/s41591-019-0561-9. Epub 2019 Sep 9. Nat Med. 2019. PMID: 31501609 Free PMC article.

2

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.

Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Willett CG, et al. Among authors: blaszkowsky ls. Nat Med. 2004 Feb;10(2):145-7. doi: 10.1038/nm988. Epub 2004 Jan 25. Nat Med. 2004. PMID: 14745444 Free PMC article. Clinical Trial.

3

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.

Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, Stuart K. Zhu AX, et al. Among authors: blaszkowsky ls. J Clin Oncol. 2006 Apr 20;24(12):1898-903. doi: 10.1200/JCO.2005.04.9130. J Clin Oncol. 2006. PMID: 16622265 Clinical Trial.

4

Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.

Wolpin BM, Clark JW, Meyerhardt JA, Earle CC, Ryan DP, Enzinger PC, Zhu AX, Blaszkowsky L, Battu S, Fuchs CS. Wolpin BM, et al. Clin Colorectal Cancer. 2006 Sep;6(3):208-13. doi: 10.3816/CCC.2006.n.037. Clin Colorectal Cancer. 2006. PMID: 17026790 Clinical Trial.

5

Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer.

Meyerhardt JA, Stuart K, Fuchs CS, Zhu AX, Earle CC, Bhargava P, Blaszkowsky L, Enzinger P, Mayer RJ, Battu S, Lawrence C, Ryan DP. Meyerhardt JA, et al. Ann Oncol. 2007 Jul;18(7):1185-9. doi: 10.1093/annonc/mdm124. Epub 2007 May 4. Ann Oncol. 2007. PMID: 17483115 Free article. Clinical Trial.

6

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.

Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, Enzinger PC, Bhargava P, Meyerhardt JA, Horgan K, Fuchs CS, Ryan DP. Zhu AX, et al. Among authors: blaszkowsky ls. Cancer. 2007 Aug 1;110(3):581-9. doi: 10.1002/cncr.22829. Cancer. 2007. PMID: 17583545 Free article. Clinical Trial.

7

Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer.

Meyerhardt JA, Zhu AX, Stuart K, Ryan DP, Blaszkowsky L, Lehman N, Earle CC, Kulke MH, Bhargava P, Fuchs CS. Meyerhardt JA, et al. Dig Dis Sci. 2008 Feb;53(2):564-70. doi: 10.1007/s10620-007-9885-2. Epub 2007 Jun 29. Dig Dis Sci. 2008. PMID: 17597402 Clinical Trial.

8

Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.

Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C, Fuchs CS. Kulke MH, et al. Among authors: blaszkowsky ls. J Clin Oncol. 2007 Oct 20;25(30):4787-92. doi: 10.1200/JCO.2007.11.8521. J Clin Oncol. 2007. PMID: 17947726

9

MDM2 promoter polymorphism and pancreatic cancer risk and prognosis.

Asomaning K, Reid AE, Zhou W, Heist RS, Zhai R, Su L, Kwak EL, Blaszkowsky L, Zhu AX, Ryan DP, Christiani DC, Liu G. Asomaning K, et al. Clin Cancer Res. 2008 Jun 15;14(12):4010-5. doi: 10.1158/1078-0432.CCR-07-4187. Clin Cancer Res. 2008. PMID: 18559624

10

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.

Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, Enzinger PC, Allen B, Clark JW, Ryan DP, Fuchs CS. Wolpin BM, et al. Among authors: blaszkowsky ls. J Clin Oncol. 2009 Jan 10;27(2):193-8. doi: 10.1200/JCO.2008.18.9514. Epub 2008 Dec 1. J Clin Oncol. 2009. PMID: 19047305 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

138 results

Search Page

Filters